Genscript Biotech Corporation (G51) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genscript Biotech Corporation (G51) has a cash flow conversion efficiency ratio of -0.045x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-93.58 Million ≈ $-109.41 Million USD) by net assets (€2.09 Billion ≈ $2.44 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see G51 company net worth for the company's overall valuation and market capitalisation.
Genscript Biotech Corporation - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Genscript Biotech Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genscript Biotech Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genscript Biotech Corporation ranked by their cash flow conversion efficiency. Explore Genscript Biotech Corporation earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Impinj Inc
NASDAQ:PI
|
0.072x |
|
Ninestar Corp
SHE:002180
|
0.017x |
|
National Storage Affiliates Trust
NYSE:NSA
|
0.059x |
|
Addsino Co Ltd
SHE:000547
|
0.047x |
|
Curbline Properties Corp.
NYSE:CURB
|
0.023x |
|
Alliance Resource Partners LP
NASDAQ:ARLP
|
0.086x |
|
Chunghwa Precision Test Tech Co Ltd
TWO:6510
|
0.053x |
|
Zhuzhou Hongda Electronics Corp Ltd Class A
SHE:300726
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Genscript Biotech Corporation (2016–2025)
The table below shows the annual cash flow conversion efficiency of Genscript Biotech Corporation from 2016 to 2025. View Genscript Biotech Corporation share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.96 Billion ≈ $4.64 Billion |
€325.52 Million ≈ $380.57 Million |
0.082x | +369.25% |
| 2024-12-31 | €4.32 Billion ≈ $5.05 Billion |
€75.65 Million ≈ $88.44 Million |
0.017x | +112.47% |
| 2023-12-31 | €2.04 Billion ≈ $2.39 Billion |
€-286.91 Million ≈ $-335.43 Million |
-0.140x | -58.98% |
| 2022-12-31 | €1.36 Billion ≈ $1.59 Billion |
€-120.29 Million ≈ $-140.63 Million |
-0.088x | +29.47% |
| 2021-12-31 | €1.09 Billion ≈ $1.28 Billion |
€-136.79 Million ≈ $-159.92 Million |
-0.125x | +32.44% |
| 2020-12-31 | €815.59 Million ≈ $953.51 Million |
€-151.09 Million ≈ $-176.64 Million |
-0.185x | -130.25% |
| 2019-12-31 | €372.30 Million ≈ $435.26 Million |
€-29.95 Million ≈ $-35.02 Million |
-0.080x | -112.90% |
| 2018-12-31 | €493.30 Million ≈ $576.72 Million |
€307.66 Million ≈ $359.69 Million |
0.624x | +566.40% |
| 2017-12-31 | €228.32 Million ≈ $266.93 Million |
€21.37 Million ≈ $24.98 Million |
0.094x | -48.24% |
| 2016-12-31 | €184.02 Million ≈ $215.14 Million |
€33.27 Million ≈ $38.90 Million |
0.181x | -- |
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Scien… Read more